This page is part of the Breast Cancer Data Logical Models and FHIR Profiles (v0.1.0: STU 1 Draft) based on FHIR R3. . For a full list of available versions, see the Directory of published versions
<CodeSystem xmlns="http://hl7.org/fhir"> <id value="oncology-OncotypeDxDCISRiskScoreInterpretationCS"/> <text> <status value="generated"/> <div xmlns="http://www.w3.org/1999/xhtml"> <p><b>BC OncotypeDxDCISRiskScoreInterpretationCS CodeSystem</b></p> <p>Intepretation of OncotypeDX DCIS (Ductal Carcinoma In Situ) Recurrence Score</p> </div> </text> <url value="http://hl7.org/fhir/us/breastcancer/CodeSystem/oncology-OncotypeDxDCISRiskScoreInterpretationCS"/> <identifier> <system value="http://hl7.org/fhir/us/breastcancer"/> <value value="oncology.OncotypeDxDCISRiskScoreInterpretationCS"/> </identifier> <version value="0.1.0"/> <name value="OncotypeDxDCISRiskScoreInterpretationCS"/> <title value="BC OncotypeDxDCISRiskScoreInterpretationCS CodeSystem"/> <status value="draft"/> <date value="2018-04-01T00:00:00+11:00"/> <publisher value="The HL7 Cancer Interoperability Group sponsored by Clinical Interoperability Council Work Group (CIC)"/> <contact> <telecom> <system value="url"/> <value value="http://standardhealthrecord.org"/> </telecom> </contact> <description value="Intepretation of OncotypeDX DCIS (Ductal Carcinoma In Situ) Recurrence Score"/> <caseSensitive value="true"/> <content value="complete"/> <count value="3"/> <concept> <code value="low_risk"/> <display value="Recurrence Score lower than 38: The cancer has a low risk of recurrence. The benefit of chemotherapy is likely to be small and will not outweigh the risks of side effects."/> <definition value="Recurrence Score lower than 38: The cancer has a low risk of recurrence. The benefit of chemotherapy is likely to be small and will not outweigh the risks of side effects."/> </concept> <concept> <code value="intermediate_risk"/> <display value="Recurrence Score of 39 up to and including 54: The cancer has an intermediate risk of recurrence. It’s unclear whether the benefits of chemotherapy outweigh the risks of side effects."/> <definition value="Recurrence Score of 39 up to and including 54: The cancer has an intermediate risk of recurrence. It’s unclear whether the benefits of chemotherapy outweigh the risks of side effects."/> </concept> <concept> <code value="high_risk"/> <display value="Recurrence Score greater than or equal to 55: The cancer has a high risk of recurrence, and the benefits of chemotherapy are likely to be greater than the risks of side effects."/> <definition value="Recurrence Score greater than or equal to 55: The cancer has a high risk of recurrence, and the benefits of chemotherapy are likely to be greater than the risks of side effects."/> </concept> </CodeSystem>